AstraZeneca (NASDAQ: AZN) adds 8,855 employee scheme shares to LSE

Rhea-AI Filing Summary

AstraZeneca PLC admitted 8,855 additional Ordinary Shares of $0.25 each to trading on the London Stock Exchange Main Market. These fully fungible shares were issued under the company’s employee share schemes between 1 July 2026 and 31 July 2026 pursuant to an existing block admission dated 29 January 2021. Following this admission, AstraZeneca has 1,551,033,389 Ordinary Shares in issue.

Key Figures

Further securities admitted: 8,855 shares Nominal value per share: $0.25 Total shares in issue: 1,551,033,389 shares +1 more

4 metrics

Further securities admitted 8,855 shares Number of additional Ordinary Shares admitted to trading

Nominal value per share $0.25 Par value of each Ordinary Share

Total shares in issue 1,551,033,389 shares Total Ordinary Shares in issue following admission

Issuance period 1 July 2026 to 31 July 2026 Period during which the new shares were issued under employee schemes

Key Terms

block admission, The Public Offers and Admissions to Trading Regulations 2024 (POATRs), fungible, employee share schemes, +1 more

5 terms

block admission regulatory

"admitted under a block admission dated 29 January 2021"

The Public Offers and Admissions to Trading Regulations 2024 (POATRs) regulatory

"in accordance with The Public Offers and Admissions to Trading Regulations 2024"

fungible financial

"Fungibility | Fully fungible with existing Ordinary Shares"

Fungible describes an asset that is interchangeable with another of the same kind because each unit holds the same value and function. For investors this matters because fungible assets are easier to trade, price, and store—think of cash or grains where one unit can replace another, unlike a unique artwork or a signed collectible which may be worth more or less depending on provenance. Fungibility affects liquidity, market efficiency, and how assets are settled or regulated.

employee share schemes financial

"Admission of shares under the Company's employee share schemes"

regulated market regulatory

"Regulated market | London Stock Exchange - Main Market"

A regulated market is an organized trading venue overseen by government or independent authorities that enforces rules on who can list, what information must be published, and how trades are executed. Think of it like a store that must pass safety inspections and display clear labels: the oversight promotes honesty, regular reporting, and fair access, which helps investors compare options, find buyers and sellers, and reduces the risk of fraud or hidden problems.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 08/03/2026 - 10:45 AM Accepted by SEC EDGAR 08/03/2026 - 10:44 AM Learn about SEC filing dates

FAQ

What did AstraZeneca PLC (AZN) disclose in this Form 6-K?

AstraZeneca PLC disclosed the admission of 8,855 additional Ordinary Shares of $0.25 each to trading on the London Stock Exchange Main Market, issued under its employee share schemes between 1 and 31 July 2026.

How many AstraZeneca (AZN) shares are in issue after the new admission?

After admitting the additional employee scheme shares, AstraZeneca PLC has a total of 1,551,033,389 Ordinary Shares in issue. This figure reflects the company’s entire issued share capital following the July 2026 admissions to trading.

On which market were AstraZeneca (AZN) shares admitted to trading?

The newly issued AstraZeneca PLC shares were admitted to trading on the London Stock Exchange – Main Market. They were admitted under an existing block admission originally dated 29 January 2021 and relate to employee share scheme issuances.

Over what period were the new AstraZeneca (AZN) employee shares issued?

The additional AstraZeneca PLC shares were issued between 1 July 2026 and 31 July 2026. They were then admitted to trading on the London Stock Exchange Main Market under the company’s existing block admission arrangements.

Are the new AstraZeneca (AZN) shares different from existing ordinary shares?

The new AstraZeneca PLC shares are described as fully fungible with existing Ordinary Shares. This means they carry the same rights and characteristics as the company’s already listed Ordinary Shares of $0.25 each.

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of August 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Admission of Further Securities to Trading

3 August 2026

Notification of Admission of Further Securities to Trading (PRM 1.6.4R)

The following notification is made in accordance with The Public Offers and Admissions to Trading Regulations 2024 (POATRs) PRM 1.6.4R.

1	Details of the issuer
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
2	Details of the transferable securities admitted to trading
a)	Name, type and identification code	Ordinary Shares of $0.25 each ISIN: GB0009895292
b)	Regulated market	London Stock Exchange - Main Market
c)	Number of further securities issued and admitted	8,855
d)	Total number of securities in issue following admission	1,551,033,389
e)	Fungibility	Fully fungible with existing Ordinary Shares
3	Admission details
a)	Date of admission	Issued between 1 July 2026 to 31 July 2026 (admitted under a block admission dated 29 January 2021)
b)	Prospectus information	Prospectus: N/A Supplementary: N/A Company's webpage: https://www.astrazeneca.com
c)	Coverage of notification	Admission of shares under the Company's employee share schemes from 1 July 2026 up to 31 July 2026, admitted to trading on the Main Market of the London Stock Exchange under the Company's existing block admission of shares dated 29 January 2021.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 03 August 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary